Published in J Clin Oncol on February 01, 2010
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol (2015) 5.00
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37
Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer (2011) 2.36
Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol (2014) 2.32
The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol (2013) 2.10
Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med (2014) 2.00
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology (2014) 1.66
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer (2013) 1.56
Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer (2014) 1.55
Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol (2012) 1.54
A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int (2013) 1.51
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Active surveillance for prostate cancer. JAMA (2010) 1.44
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int (2010) 1.40
Physician social networks and variation in prostate cancer treatment in three cities. Health Serv Res (2011) 1.40
Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun (2016) 1.39
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open (2014) 1.38
Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer (2011) 1.26
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer (2014) 1.25
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis (2013) 1.23
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol (2015) 1.18
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer (2011) 1.16
Biomarkers in prostate cancer: what's new? Curr Opin Oncol (2014) 1.16
Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15
Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol (2012) 1.14
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial. Urol Oncol (2011) 1.08
Prognostic factors for failure after prostatectomy. J Cancer (2010) 1.08
Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis (2012) 1.06
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol (2016) 1.04
Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer (2011) 1.04
The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J (2013) 1.03
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget (2014) 1.02
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol (2015) 1.01
Factors influencing patients' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr (2012) 1.00
The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat (2011) 0.99
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak (2010) 0.98
Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med (2012) 0.98
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
Salvage prostatectomy post-definitive radiation therapy: The Vancouver experience. Can Urol Assoc J (2015) 0.96
Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys (2011) 0.96
Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol (2013) 0.95
Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis (2015) 0.95
Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med (2013) 0.93
The example of CaPSURE: lessons learned from a national disease registry. World J Urol (2011) 0.92
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Active surveillance: the Canadian experience with an "inclusive approach". J Natl Cancer Inst Monogr (2012) 0.92
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. Urol Oncol (2013) 0.92
Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol (2016) 0.91
Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer. Can Urol Assoc J (2015) 0.91
Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions. J Natl Cancer Inst Monogr (2012) 0.91
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
The role of radical prostatectomy in high-risk prostate cancer. Prostate Int (2013) 0.89
Adherence to performance measures and outcomes among men treated for prostate cancer. J Urol (2014) 0.89
5-α reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med (2011) 0.89
Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int (2014) 0.89
Variation in receipt of radiation therapy after breast-conserving surgery: assessing the impact of physicians and geographic regions. Med Care (2013) 0.89
Chemoprevention of prostate cancer: an updated view. World J Urol (2012) 0.89
Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer (2013) 0.88
Increasing use of observation among men at low risk for prostate cancer mortality. J Urol (2014) 0.88
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol (2016) 0.88
Hospital racial composition and the treatment of localized prostate cancer. Cancer (2011) 0.88
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol (2015) 0.87
Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer. J Magn Reson Imaging (2012) 0.87
Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy. Cancer (2013) 0.87
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel) (2014) 0.87
A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol (2014) 0.87
Prostate cancer: Growth of AS in the USA signals reduction in overtreatment. Nat Rev Urol (2015) 0.86
Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis (2011) 0.86
The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. PLoS One (2012) 0.86
Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol (2010) 0.86
Radical prostatectomy improves and prevents age dependent progression of lower urinary tract symptoms. J Urol (2013) 0.86
Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance. BJU Int (2011) 0.86
Physician social networks and variation in rates of complications after radical prostatectomy. Value Health (2014) 0.84
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol (2013) 0.84
Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. Onco Targets Ther (2013) 0.84
Multicriteria decision analysis in oncology. Health Expect (2014) 0.83
Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am (2014) 0.83
Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. Eur Urol (2015) 0.83
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Who you are and where you live: how race and geography affect the treatment of medicare beneficiaries. Health Aff (Millwood) (2004) 4.25
Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood) (2004) 4.19
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology (1996) 3.26
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol (2008) 2.40
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer (2005) 1.65
Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU Int (2007) 1.52
Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer (2005) 1.33
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Regression of low-grade squamous intra-epithelial lesions in young women. Lancet (2004) 2.98
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
Urology resident publication output and its relationship to future academic achievement. J Urol (2010) 1.85
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol (2007) 1.70
Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol (2010) 1.70
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer (2007) 1.68
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A (2008) 1.61
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59
Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol (2012) 1.56
Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol (2013) 1.55
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol (2005) 1.52
Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int (2010) 1.52
Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol (2006) 1.50
Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol (2013) 1.49
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49
Treatment trends for stage I renal cell carcinoma. J Urol (2011) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol (2005) 1.46
Modifying urology residency training: time to speed up or slow down? J Urol (2006) 1.44
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology (2008) 1.39
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2008) 1.39
Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. Urology (2011) 1.39
Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res (2011) 1.38
Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol (2005) 1.37
Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer (2007) 1.37
Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol (2008) 1.35
Geographic distribution of urologists throughout the United States using a county level approach. J Urol (2008) 1.35